Group 1: Market Overview - Small-cap stocks delivered marginal gains in Q4 2025, with the Russell 2000® Value Index outperforming the Russell 2000® Growth Index [1] - The Russell 2000 Growth Index returned 13.01%, while the Russell 2000 Value Index gained 12.58% in 2025 [1] - The firm anticipates a favorable year ahead for equity markets, highlighting potential opportunities in various sectors [1] Group 2: Company Spotlight - BrightSpring Health Services, Inc. - BrightSpring Health Services, Inc. (NASDAQ:BTSG) is a US-based healthcare services platform focusing on specialty pharmaceuticals and complex patient care [3] - As of February 13, 2026, BrightSpring's stock closed at $38.86 per share, with a one-month return of -1.38% and a 75.33% increase over the past twelve months [2] - The company reported significant revenue and EBITDA growth, driven by contract wins for high-margin drugs treating complex conditions [3] - BrightSpring was added to several important S&P indices, including the S&P SmallCap 600® and the S&P 600 Healthcare Sector [3] Group 3: Hedge Fund Interest - BrightSpring Health Services, Inc. was held by 48 hedge fund portfolios at the end of Q3, a decrease from 51 in the previous quarter [5] - While the company shows investment potential, certain AI stocks are considered to offer greater upside potential with less downside risk [5]

Core Viewpoint - McKesson Corporation is expected to report significant revenue and earnings growth in the fourth quarter of fiscal 2025, driven by the adoption of GLP-1 weight loss drugs, demand for specialty pharmaceuticals, and investments in technology and distribution [1][3][16]. Revenue Growth Drivers - The rapid adoption of GLP-1 weight loss drugs and sustained demand for branded pharmaceuticals have significantly fueled McKesson's revenue growth [1][6]. - A rebound in primary care visits has also supported top-line growth in the last two reported quarters [2]. - Investments in expanding distribution centers and integrating artificial intelligence into services have bolstered revenues [2][20]. Earnings Estimates - The Zacks Consensus Estimate for earnings is $9.81 per share, reflecting a 58.7% year-over-year improvement [3]. - The consensus revenue estimate is $93.7 billion, indicating a 22.7% year-over-year surge [3]. Segment Performance Insights - The U.S. Pharmaceutical segment is expected to show steady growth, driven by strong demand for specialty pharmaceuticals, particularly oncology treatments [4]. - The Prescription Technology Solutions segment is projected to see revenues of $1.33 billion, a 12.3% year-over-year improvement, supported by strong demand for technology services [9]. - The Medical Surgical Solutions segment is estimated to generate $2.8 billion, reflecting a 1.5% decline year-over-year due to less demand for illness season products [11]. Strategic Initiatives - McKesson has expanded its distribution network by opening new technologically advanced centers and acquiring stakes in oncology-related ventures, which are expected to enhance its service delivery and revenue growth [17][18]. - The company is leveraging advanced technologies, particularly AI, to improve service delivery and streamline operations [20]. Market Position and Performance - McKesson's shares have gained 24.1% this year, outperforming the industry, which has declined by 2.1% [21]. - The company is recognized for its extensive distribution network, which includes over 50,000 pharmacies and nearly 900,000 healthcare providers, enhancing its appeal to pharmaceutical manufacturers [19].